Generate Biomedicines Stock
HealthTechLooking to sell Generate Biomedicines stock or options?
Generate Biomedicines has developed an innovative generative biology platform aimed at creating new drugs across various protein modalities and therapeutic areas. By utilizing machine learning, the company deciphers the genetic code that dictates protein function, allowing for the generation of antibodies, peptides, enzymes, as well as cell and gene therapies tailored to any therapeutic requirement. This enables researchers to deliver new medicinal solutions to patients effectively.
Alumni Ventures, Samsung Biologics Company, ARCH Venture Partners, Pictet Alternative Advisors, T. Rowe Price Group, Nvidia, Flagship Pioneering, Partners Investment, ARK Venture Fund, Novartis Institutes for BioMedical Research, Abu Dhabi Investment Authority, Amgen, Fidelity Management & Research Company, BakerBridge Capital, Alaska Permanent Fund, Modi Ventures, Altitude Life Science Ventures, NVentures (Santa Clara), Morningside Group, March Capital, Maps Capital, Mirae Asset Capital.